Amgen (AMGN) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Core Insights - Amgen's upcoming quarterly earnings report is projected to show earnings of $4.15 per share, a 4.8% increase year-over-year, with revenues expected to reach $7.96 billion, reflecting a 6.8% growth compared to the previous year [1] - Over the last 30 days, the consensus EPS estimate has been revised downward by 1.6%, indicating a reassessment by analysts [1][2] Revenue and Product Sales Estimates - Analysts forecast 'Product Sales- BLINCYTO- Total' to be $332.73 million, marking a 36.4% increase from the prior year [4] - 'Product Sales- Repatha- Total' is expected to reach $616.47 million, indicating a 19.2% year-over-year growth [4] - 'Product Sales- KYPROLIS- Total' is estimated at $381.49 million, reflecting a 1.5% increase from the previous year [4] - 'Product Sales- Vectibix- Total' is projected at $248.09 million, a slight increase of 0.4% year-over-year [5] - 'Product Sales- Neulasta- U.S.' is expected to decline to $67.86 million, a decrease of 22% from the prior year [5] - 'Product Sales- Neulasta- ROW' is estimated at $26.10 million, indicating a 15.8% decline year-over-year [5] - 'Product Sales- EPOGEN- U.S.' is projected to be $30.98 million, reflecting a 24.4% decrease [6] - 'Product Sales- Repatha- ROW' is expected to reach $295.07 million, a 20.9% increase from the previous year [6] - 'Product Sales- Repatha- U.S.' is projected at $331.22 million, indicating a 21.3% increase year-over-year [6] - 'Product Sales- KYPROLIS- ROW' is estimated at $147.40 million, reflecting a 3.8% increase [7] - 'Product Sales- BLINCYTO- U.S.' is expected to be $207.37 million, a 35.5% increase year-over-year [7] - 'Product Sales- BLINCYTO- ROW' is projected at $117.02 million, indicating a 28.6% increase from the prior year [7] Stock Performance - Over the past month, Amgen's shares have decreased by 8.5%, compared to a 4.3% decline in the Zacks S&P 500 composite [7]